Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.

doi:10.1007/s10549-020-05603-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.

Breast cancer research and treatment - 1 Jun 2020

O'Donnell Peter H, Trubetskoy Vassily, Nurhussein-Patterson Ashley, Hall Julianne P, Nath Aritro, Huo Dezheng, Fleming Gini F, Ingle James N, Abramson Vandana G, Morrow P K, Storniolo Anna Maria, Forero Andres, Van Poznak Catherine, Liu Minetta C, Chang Jenny C, Merkel Douglas E, Peppercorn Jeffrey M, Rugo Hope S, Dees E Claire, Hahn Olwen M, Hoffman Philip C, Rosner Gary L, Huang R Stephanie, Ratain Mark J, Cox Nancy, Olopade Olufunmilayo I, Wolff Antonio C, Dolan M Eileen, Nanda Rita

Abstract excerpt

PURPOSE: Capecitabine is important in breast cancer treatment but causes diarrhea and hand-foot syndrome (HFS), affecting adherence and quality of life. We sought to identify pharmacogenomic predictors of capecitabine toxicity using a novel monitoring tool. METHODS: Patients with metastatic breast cancer were prospectively treated with capecitabine (2000 mg/m2/day, 14 days on/7 off). Patients completed in-person...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Drug-Related Side Effects and Adverse Reactions

Share to Ferredoxin-NADP Reductase

Share to Follow-Up Studies

Share to Germ-Line Mutation

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Quality of Life

Source

Open in PubMed

Identifiers

PMID: 32378051
DOI: 10.1007/s10549-020-05603-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.PMID 32378051Read ↗

Polymorphisms of MTHFR and TYMS predict capecitabine‐induced hand‐foot syndrome in patients with metastatic breast cancerSemantic proximity Read ↗

Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer.Semantic proximity Read ↗

New advances in DPYD genotype and risk of severe toxicity under capecitabine.Semantic proximity Read ↗

A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.Semantic proximity Read ↗

Gene expression responses reflecting 5-FU-induced toxicity: Comparison between patient colon tissue and 3D human colon organoidsSemantic proximity Read ↗

Identification of novel germline polymorphisms governing capecitabine sensitivity.Semantic proximity Read ↗

Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.Semantic proximity Read ↗

Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.Semantic proximity Read ↗

Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.Semantic proximity Read ↗

Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYDSemantic proximity Read ↗

Highlight on DPYD gene polymorphisms and treatment by capecitabine (.).Semantic proximity Read ↗

A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.